Abstract. Background: The present study examines the effect of piroxicam, a non-steroidal anti-inflammatory drug, on tumor development in Mlh1+/â/Apc1638N/+ ...
ANTICANCER RESEARCH 27: 3807-3812 (2007)
Piroxicam Increases Colon Tumorigenesis and Promotes Apoptosis in Mlh1+/–/Apc1638N/+ Mice EMANUELA PALMERINI1, KUNHUA FAN2, KAN YANG2, MAURO RISIO3, WINFRIED EDELMANN4, MARTIN LIPKIN2 and GUIDO BIASCO5 1Department
of Musculoskeletal Oncology, Istituti Ortopedici Rizzoli, Bologna, Italy; Cancer Research Laboratory, Department of Medicine (Gastroenterology), Weill Medical College of Cornell University, New York, NY, U.S.A.; 3Department of Pathology, Institute for Cancer Research and Treatment, Candiolo-Torino, Italy; 4Albert Einstein College of Medicine, Bronx, NY, U.S.A.; 5Institute of Hematology and Medical Oncology "L. & A. Seràgnoli", University of Bologna, Bologna, Italy 2Strang
Abstract. Background: The present study examines the effect of piroxicam, a non-steroidal anti-inflammatory drug, on tumor development in Mlh1 +/–/Apc1638 N/+ mice, in a preclinical model of human colon cancer. Materials and Methods: Mice were fed AIN-76A diet alone or premixed with piroxicam (60 ppm) for 9 weeks. The number, location and volume of tumors, and apoptosis in the flat mucosa were determined in small and large intestine. Results: Piroxicam reduced the number of tumors per mouse by 80% in the small intestine (0.1 vs. 0.5, p
